Low Back Pain (Central Nervous System) - Drugs In Development, 2021

July 2021 | 164 pages | ID: L44D470DB5E8EN
Global Markets Direct

Abstracts

Low Back Pain (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain - Drugs In Development, 2021, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 18, 11, 4, 2 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Low Back Pain - Overview
Low Back Pain - Therapeutics Development
Low Back Pain - Therapeutics Assessment
Low Back Pain - Companies Involved in Therapeutics Development
Low Back Pain - Drug Profiles
Low Back Pain - Dormant Projects
Low Back Pain - Discontinued Products
Low Back Pain - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Low Back Pain, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Companies, 2021 (Contd..2)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Low Back Pain - Pipeline by Ache Laboratorios Farmaceuticos SA, 2021
Low Back Pain - Pipeline by Adynxx Inc, 2021
Low Back Pain - Pipeline by Allodynic Therapeutics LLC, 2021
Low Back Pain - Pipeline by Amplicore Inc, 2021
Low Back Pain - Pipeline by AnGes Inc, 2021
Low Back Pain - Pipeline by Axsome Therapeutics Inc, 2021
Low Back Pain - Pipeline by BioRestorative Therapies Inc, 2021
Low Back Pain - Pipeline by Bol Pharma, 2021
Low Back Pain - Pipeline by Camurus AB, 2021
Low Back Pain - Pipeline by Causeway Therapeutics Ltd, 2021
Low Back Pain - Pipeline by Creative Medical Technology Holdings Inc, 2021
Low Back Pain - Pipeline by Daewon Pharmaceutical Co Ltd, 2021
Low Back Pain - Pipeline by Eli Lilly and Co, 2021
Low Back Pain - Pipeline by Ethismos Research Inc, 2021
Low Back Pain - Pipeline by Evero Health Ltd, 2021
Low Back Pain - Pipeline by Frontier Biotechnologies Inc, 2021
Low Back Pain - Pipeline by Gador SA, 2021
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2021
Low Back Pain - Pipeline by Imbrium Therapeutics LP, 2021
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc, 2021
Low Back Pain - Pipeline by Inspyr Therapeutics Inc, 2021
Low Back Pain - Pipeline by Intec Pharma Ltd, 2021
Low Back Pain - Pipeline by Laboratorios Silanes SA de CV, 2021
Low Back Pain - Pipeline by MD Biosciences GmbH, 2021
Low Back Pain - Pipeline by Mesoblast Ltd, 2021
Low Back Pain - Pipeline by Navipharm Co Ltd, 2021
Low Back Pain - Pipeline by Panacea Biotec Ltd, 2021
Low Back Pain - Pipeline by Persica Pharmaceuticals Ltd, 2021
Low Back Pain - Pipeline by Pfizer Inc, 2021
Low Back Pain - Pipeline by Qingdao Chia Tai Haier Pharmaceutical Co Ltd, 2021
Low Back Pain - Pipeline by Scilex Holding Co, 2021
Low Back Pain - Pipeline by Sclnow Biotechnology Co Ltd, 2021
Low Back Pain - Pipeline by Shionogi & Co Ltd, 2021
Low Back Pain - Pipeline by Spine BioPharma LLC, 2021
Low Back Pain - Pipeline by Stayble Therapeutics AB, 2021
Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd, 2021
Low Back Pain - Pipeline by Tris Pharma Inc, 2021
Low Back Pain - Pipeline by Valenta Pharm, 2021
Low Back Pain - Pipeline by Vertanical GmbH, 2021
Low Back Pain - Pipeline by WEX Pharmaceuticals Inc, 2021
Low Back Pain - Pipeline by Xgene Pharmaceutical Inc, 2021
Low Back Pain - Dormant Projects, 2021
Low Back Pain - Dormant Projects, 2021 (Contd..1)
Low Back Pain - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Low Back Pain, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021